Neurocrine Biosciences (NBIX) Non-Current Assets (2010 - 2026)

Neurocrine Biosciences has reported Non-Current Assets for 17 years, with the latest figure at $2.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 20.5% year-over-year to $2.5 billion; the trailing twelve-month figure through Mar 2026 stood at $8.8 billion (up 20.3% YoY), and the FY2025 full-year result was $2.1 billion, up 5.76% from the prior year.
• Non-Current Assets for Q1 2026 stood at $2.5 billion, up from $2.1 billion in the prior quarter.
• The five-year high for Non-Current Assets was $2.5 billion in Q1 2026, with the low at $915.2 million in Q4 2022.
• Historically, Non-Current Assets has averaged $1.6 billion across 5 years, with a median of $1.6 billion in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Assets dropped 17.7% — and 2024, when it jumped 80.52%.
• Neurocrine Biosciences' Non-Current Assets stood at $915.2 million in 2022, then surged by 79.68% to $1.6 billion in 2023, then advanced by 21.26% to $2.0 billion in 2024, then rose by 5.76% to $2.1 billion in 2025, then climbed by 17.13% to $2.5 billion in 2026.
• The last three Non-Current Assets figures came in at $2.5 billion (Q1 2026), $2.1 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.